Albireo Appoints New Members to Board of Directors
10 août 2022 08h30 HE
|
Albireo Pharma, Inc.
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children’s Hospital, bring significant global drug...
Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
03 août 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo to Report Q2 2022 Financial Results on August 15, 2022
01 août 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26 juil. 2022 16h30 HE
|
Albireo Pharma, Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the grant of inducement restricted...
The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC
06 juil. 2022 08h30 HE
|
Albireo Pharma, Inc.
First successful global gold standard pediatric Phase 3 trial ever conducted in cholestatic liver disease PEDFIC 1 & 2 studies were foundational for the approval of Bylvay in the U.S. and Europe...
Albireo to Present at the William Blair Biotech Focus Conference 2022
30 juin 2022 08h00 HE
|
Albireo Pharma, Inc.
BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair...
Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress
24 juin 2022 08h30 HE
|
Albireo Pharma, Inc.
Four presentations highlight newest data from landmark Phase 3 PEDFIC 1 and PEDFIC 2 trials, largest studies completed in PFICNew analysis show potential for greater response and higher proportion of...
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
23 juin 2022 08h30 HE
|
Albireo Pharma, Inc.
New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic...
Albireo to Present New Data at the EASL International Liver Congress™ 2022
08 juin 2022 08h30 HE
|
Albireo Pharma, Inc.
– Five abstracts accepted, long-term data confirmed durable efficacy with Bylvay™ (odevixibat), with demonstrated improvement in quality of life, growth, and sleep measurements, and hepatic biomarkers...
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
07 juin 2022 08h30 HE
|
Albireo Pharma, Inc.
– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) – Three oral presentations discuss long-term safety, tolerability and improved quality of life,...